Description
For diagnosis of acute leukemia
Acute leukemia panel – Comprehensive -CD3,CD4,CD5,CD7,CD8,CD10,CD19,CD22,CD13,CD14,CD15,CD33,CD117,CD34,CD41,CD61,GLYCOPHORIN A, HLADR, cCD3, cCD22, cCD79a, cMPO, TdT
For diagnosis of acute leukemia
TAT: 1 day
Specimen Type: Blood / Bone marrow aspirate
Flowcytometry Panel Test
Other Tests
-
238%
CLPD panel-1 CD5,,CD23,CD19,CD3,CD10,CD79b,CD38,CD200, Kappa, Lambda
Kappa,Lamda,CD38,19,45,5,10,20,3,4,5,7,56,200,23,43,49d,FMC-7, Additiional CD103,123,25,11c
CLPD panel-1 CD5,,CD23,CD19,CD3,CD10,CD79b,CD38,CD200, Kappa, Lambda
Kappa,Lamda,CD38,19,45,5,10,20,3,4,5,7,56,200,23,43,49d,FMC-7, Additiional CD103,123,25,11c
-
231%
CD 34
CD34+ cell quantification is necessary to determine the optimal timing and to confirm the adequacy of Peripheral Blood Stem Cell (PBSC) harvests. This assay also helps to determine when to perform Bone marrow stem cell transplants; whether to continue Apheresis and to assess bone marrow and Cord blood viability. CD34+ absolute count is a critical parameter for rapid and sustained engraftment.
CD 34
CD34+ cell quantification is necessary to determine the optimal timing and to confirm the adequacy of Peripheral Blood Stem Cell (PBSC) harvests. This assay also helps to determine when to perform Bone marrow stem cell transplants; whether to continue Apheresis and to assess bone marrow and Cord blood viability. CD34+ absolute count is a critical parameter for rapid and sustained engraftment.
-
202%
B-ALL Monitoring Minimal Residual Disease(MRD) Detection by Flow Cytometry
Minimal residual disease B ALL
B-ALL Monitoring Minimal Residual Disease(MRD) Detection by Flow Cytometry
Minimal residual disease B ALL
-
269%
T-ALL Monitoring Minimal Residual Disease(MRD) Detection by Flow Cytometry
T ALL minimal residual disease
T-ALL Monitoring Minimal Residual Disease(MRD) Detection by Flow Cytometry
T ALL minimal residual disease
Reviews
There are no reviews yet.